Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challengesMichail Kokkorakis, Christos S. Mantzoros, Rohit Loomba et al.|Metabolism|2024Cited by 138
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservationKonstantinos Stefanakis, Christos S. Mantzoros, Michail Kokkorakis|Metabolism|2024Cited by 112